{"id":"NCT02872116","sponsor":"Bristol-Myers Squibb","briefTitle":"Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer","officialTitle":"A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination With Oxaliplatin Plus Fluoropyrimidine Versus Oxaliplatin Plus Fluoropyrimidine in Subjects With Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-10-12","primaryCompletion":"2020-05-27","completion":"2024-06-06","firstPosted":"2016-08-19","resultsPosted":"2022-06-28","lastUpdate":"2025-08-07"},"enrollment":2031,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Gastric Cancer","Gastroesophageal Junction Cancer","Esophageal Adenocarcinoma"],"interventions":[{"type":"DRUG","name":"Nivolumab","otherNames":["Opdivo","BMS-936558"]},{"type":"DRUG","name":"Ipilimumab","otherNames":["Yervoy","BMS-734016"]},{"type":"DRUG","name":"Oxaliplatin","otherNames":[]},{"type":"DRUG","name":"Capecitabine","otherNames":[]},{"type":"DRUG","name":"Leucovorin","otherNames":[]},{"type":"DRUG","name":"Fluorouracil","otherNames":[]}],"arms":[{"label":"Nivolumab + Ipilimumab","type":"EXPERIMENTAL"},{"label":"XELOX (Oxaliplatin + Capecitabine)","type":"ACTIVE_COMPARATOR"},{"label":"FOLFOX (Oxaliplatin + Leucovorin + Fluorouracil)","type":"ACTIVE_COMPARATOR"},{"label":"Nivolumab + XELOX","type":"EXPERIMENTAL"},{"label":"Nivolumab + FOLFOX","type":"EXPERIMENTAL"}],"summary":"The main purpose of this study is to compare how long patients with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab or nivolumab and chemotherapy compared with patients receiving chemotherapy alone.","primaryOutcome":{"measure":"Overall Survival (OS) in Participants Treated With Nivolumab Plus Chemotherapy vs Chemotherapy With PD-L1 CPS ≥ 5","timeFrame":"From the date of randomization up to the date of death, up to approximately 17 months","effectByArm":[{"arm":"Arm 1: Nivolumab + Chemotherapy (XELOX or FOLFOX)","deltaMin":14.39,"sd":null},{"arm":"Arm 2a: Chemotherapy (XELOX or FOLFOX)","deltaMin":11.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":179,"countries":["United States","Argentina","Australia","Brazil","Canada","Chile","China","Colombia","Czechia","France","Germany","Greece","Hong Kong","Hungary","Israel","Italy","Japan","Mexico","Peru","Poland","Portugal","Romania","Russia","Singapore","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["40632415","38382001","37713657","36919706","36121651","34102137"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","http://www.BMSClinicalTrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":529,"n":782},"commonTop":["Nausea","Nausea","Anaemia","Anaemia","Diarrhoea"]}}